<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884192</url>
  </required_header>
  <id_info>
    <org_study_id>CONSIST</org_study_id>
    <nct_id>NCT03884192</nct_id>
  </id_info>
  <brief_title>Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC</brief_title>
  <acronym>CONSIST</acronym>
  <official_title>CONSIST: A Phase III Randomized Control Study of Consolidation Sintilimab (IBI308) After Concurrent Chemoradiation Versus Chemoradiation Alone in Patients With Unresectable Local Advanced Stage III NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Cancer Hospital and Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Cancer Hospital and Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, randomized, control phase III trial, to compare the
      efficacy and safety of consolidation therapy with sintilimab (IBI308) versus best supported
      care (BSC), in unresectable stage III NSCLC patients who do not experience disease
      progression after initial concurrent chemoradiation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, multi-center, randomized, control study of sintilimab versus BSC in
      unresectable local advanced stage III NSCLC patients without disease progression after
      concurrent chemoradiation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 24 months after enrollment or study close</time_frame>
    <description>PFS (per RECIST 1.1 as assessed by the investigator) will be defined as the time from the date of randomisation until the date of objective disease progression or death (by any cause in the absence of progression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 24 months after enrollment or study close</time_frame>
    <description>OS (per RECIST 1.1 as assessed by the investigator) is defined as the time from the date of randomisation until death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 months after enrollment or study close</time_frame>
    <description>ORR (per RECIST 1.1 as assessed by the investigator) is defined as the proportion (%) of patients with at least one visit response of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 24 months after enrollment or study close</time_frame>
    <description>DCR (per RECIST 1.1 as assessed by the investigator) is defined as the proportion (%) of patients with at least one visit response of complete response (CR) or partial response (PR), or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>up to 24 months after enrollment or study close</time_frame>
    <description>DoR (per RECIST 1.1 as assessed by the investigator) is defined as the time from the date for first documented response of complete response (CR) or partial response (PR) until the date for the first documented response of progressive disease (PD) or death in the absence of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Rate at 12/18 months</measure>
    <time_frame>From the date of randomization until the Kaplan-Meier estimate of PFS at 12/18months</time_frame>
    <description>PFS rate at 12/18 months is defined as the proportion (%) of patients who are alive and progression free at 12 and 18months from the date of randomisation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related Adverse Events (AEs)</measure>
    <time_frame>From the date of randomization to 90 days after last dose of study treatment</time_frame>
    <description>The grade of AEs and the number of patients with AEs are assessed by the investigator based on CTCAE v4.03 from the date of randomization to 90 days after last dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Carcinoma, Non-Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Sintilimab Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab consolidation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation Sintilimab</intervention_name>
    <description>Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.</description>
    <arm_group_label>Sintilimab Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent before initiation of any study procedures

          2. Age ≥ 18 years and ≤ 75 years

          3. Histologically or cytologically confirmed NSCLC, with unresectable local advanced
             disease (stage III according to NSCLC staging version 8)

          4. Expected survival over 3 months

          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          6. At least 1 measurable disease according to RECIST 1.1

          7. Pulmonary function: forced expiratory volume at one second (FEV1) &gt; 1 liter(L)

          8. Patient must not have received any anti-cancer therapy for the purpose of treating
             lung cancer. However, exploratory thoracotomy, mediastinoscopy, excision biopsy, and
             other kinds of surgery for diagnosis and staging purpose is acceptable. Patients with
             local or regional recurrent disease after pneumonectomy is allowed to participate if
             they meet other inclusion criteria (e.g. stage III, inappropriate for re-operation).

          9. For all female patients of childbearing potential, a negative pregnancy test (either
             urine or serum) must be obtained within 3 days before the first dose (Cycle 1, Day 1)
             of study treatment. If a urine pregnancy test shows an unconfirmed result, a serum
             pregnancy test must be performed.

         10. Adequate hematopoietic function, defined as: absolute neutrophil count (ANC) ≥ 1.5 x
             10*9/L; platelet count ≥100 x 10*9/L; hemoglobin ≥90 g/L [no blood transfusion within
             7 days or not erythropoietin (EPO) dependent]

         11. Adequate liver function, defined as: total serum bilirubin ≤ 1.5 x upper limit of
             normal (ULN); serum alanine transaminase (ALT) and aspartic transaminase (AST) ≤ 2.5 x
             ULN, with no liver transplantation

         12. Adequate renal function, defined as: serum creatinine ≤ 1.5 x ULN or calculated
             creatinine-clearance ≥ 60 ml/min (Cockcroft-Gault). Urine protein less than 2+ by
             urinalysis or 24-hour urinary protein quantity &lt; 1g

         13. Adequate coagulation function, defined as: international normalized ratio (INR) or
             prothrombin time (PT) ≤ 1.5 x ULN. For patients receiving anticoagulant therapy can be
             enrolled if PT is within the range defined by anticoagulant therapy.

         14. Myocardial enzymes are within normal range

         15. All subjects of childbearing potential must agree to use efficient contraceptive
             methods that result in a failure rate of &lt; 1% per year during the study treatment
             period and for at least 180 days after discontinuation from study treatment.

        Exclusion Criteria:

          1. Being treated by other investigational drugs within an interventional study, or have
             received any investigational drugs or instruments within 4 weeks prior to the first
             dose of study treatment

          2. Being enrolled in other interventional studies, unless they are observational studies
             or during the follow-up stage of an interventional study

          3. NSCLC histology with small cell lung cancer (SCLC) components

          4. Active or autoimmune disease history (within the past 2 years), or history of immune
             deficiency

          5. Previous immune therapy including: anti PD-1, anti PD-L1, anti PD-L2 or treatment
             targeting other co-stimulatory or co-inhibitory T-cell receptors [e.g. cytotoxic
             T-lymphocyte-associated protein 4 (CTLA-4), OX-40, and CD137]

             a) Systemic therapy with Chinese patent medicine or drugs of immunoregulation effect
             (including thymosin, interferon, interleukin, unless local delivery for controlling
             pleural effusion) within 2 weeks prior to the first dose of study treatment, or major
             surgery within 4 weeks prior to the first dose of study treatment

          6. Clinical evidence of active diverticulitis, abdominal abscess, or gastrointestinal
             obstruction

          7. Previous organ or blood system transplantation

          8. Known allergic to pemetrexed, paclitaxel, etoposide, cisplatin, carboplatin,
             sintilimab component and/or any excipients

          9. A history of active autoimmune disease requiring systemic treatment (e.g. using drugs
             for disease remission, corticosteroids or immunosuppressor) within 2 years prior to
             the first dose of study treatment. Substitution therapy (e.g. thyroxine, insulin or
             physiological corticosteroids for treating adrenal or pituitary dysfunction) is not
             considered as a systemic treatment.

             a) Diagnosis as immunodeficiency, or being treated with systemic glucocorticoid or
             other kinds of immunosuppressor within 7 days prior to the first dose of study
             treatment. A physiological dose of glucocorticoid (≤10 mg/day prednisone or equivalent
             dose of other steroids) is permitted.

         10. Previously diagnosis as other malignant tumors within 5 years prior to the first dose
             of study treatment, with the exception of: skin basal cell carcinoma or squamous cell
             carcinoma with radical treatment, and/or carcinoma in situ underwent radical resection

         11. History of non-infectious pneumonitis requiring treatment with glucocorticoid within 1
             year prior to the first dose of study treatment, or currently existed interstitial
             lung disease

         12. Active infectious that required systemic therapy

         13. Know psychiatric illness or drug abuse that would limit compliance with study
             requirements

         14. Know human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive)

         15. Untreated active viral hepatitis B (HBV)

             Patients with HBV who meet the following criteria are also eligible:

               1. HBV virus load (VL) &lt;1000 copy/ml (200 IU/ml), and patients must continuously
                  receive anti-HBV therapy during all through study treatment phase to prevent
                  virus activation

               2. Patients with a result of anti-HBc(+)、HBsAg (-)、anti-HBs (-) 和 HBV VL (-) are not
                  required to receive prophylactic anti-HBV therapy, but must be closely monitored
                  for virus re-activation

         16. Patients with active HCV infection (HCV antibody positive and HCV-RNA &gt; the lower
             detection limit)

         17. History or evidence of disease, treatment or laboratory abnormalities that would
             interfere the study outcome, prevent patients from participating entirely, or
             ineligible to enroll per the investigators' judgement

         18. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Yu, Ph.D</last_name>
      <phone>+86-531-67626142</phone>
      <email>sdyujinming@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. Review.</citation>
    <PMID>20351327</PMID>
  </reference>
  <reference>
    <citation>Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017 Feb 10;8(1):1-20. doi: 10.5306/wjco.v8.i1.1. Review.</citation>
    <PMID>28246582</PMID>
  </reference>
  <reference>
    <citation>Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK, Lee KC, Chen M, Kim DW, Kim HK, Min YJ, Kang JH, Choi JH, Kim SW, Zhu G, Wu YL, Kim SR, Lee KH, Song HS, Choi YL, Sun JM, Jung SH, Ahn MJ, Park K. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.</citation>
    <PMID>26150444</PMID>
  </reference>
  <reference>
    <citation>Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Apr;15(4):504-535.</citation>
    <PMID>28404761</PMID>
  </reference>
  <reference>
    <citation>Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.</citation>
    <PMID>25601342</PMID>
  </reference>
  <reference>
    <citation>Tsujino K, Kurata T, Yamamoto S, Kawaguchi T, Kubo A, Isa S, Hasegawa Y, Ou SH, Takada M, Ando M. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol. 2013 Sep;8(9):1181-9. doi: 10.1097/JTO.0b013e3182988348.</citation>
    <PMID>23883782</PMID>
  </reference>
  <reference>
    <citation>Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.</citation>
    <PMID>28885881</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Cancer Hospital and Institute</investigator_affiliation>
    <investigator_full_name>Jinming Yu</investigator_full_name>
    <investigator_title>President of Shandong Cancer Hospital and Institute</investigator_title>
  </responsible_party>
  <keyword>Locally advanced</keyword>
  <keyword>Stage III Non-Small Cell Lung Cancer</keyword>
  <keyword>Unresectable Non-Small Cell Lung Cancer</keyword>
  <keyword>Concurrent Chemoradiation</keyword>
  <keyword>Immune-mediated cancer therapy</keyword>
  <keyword>PD-1</keyword>
  <keyword>Sintilimab</keyword>
  <keyword>IBI308</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

